Exir Bio is an emerging entity in the biomedical sector that employs stem cells and primary cells derived from non-human primates for conducting in vitro evaluations of drug efficacy and safety. The platform significantly reduces, refines, and replaces the utilization of non-human primates in biomedical studies, accelerating the pace of preclinical safety evaluations. This is in line with FDA Modernization Act 2.0 and advancement of New Approach Methods (NAMs) for drug efficacy and safety assessments.
We have pioneered proprietary technology that harnesses primate stem cells, paving the way for enhanced drug screening, gene manipulation, and cell therapy. By adopting the in vitro approach, Exir Bio successfully eliminates the need for live monkeys in biomedical investigations. This leads to a considerable reduction in time and expenses for early drug discovery, efficacy, and safety screening. In addition to being a more time and cost-effective method, it also promotes a more humane approach to biomedical research.
Company Details
- Employees
- 10
- Founded
- 2022
- Address
- Sunnyvale, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.exirbio.com
- HQ
- Sunnyvale
Exir Bio Questions
Exir Bio's website is http://www.exirbio.com
Exir Bio's LinkedIn profile is https://www.linkedin.com/company/exir-bio
Exir Bio has
10 employees.
View email and phone details for 10
employees at Exir Bio.
Exir Bio's industry is
Biotechnology Research
Exir Bio's top competitors are
Veranova,
Restem,
Taproot Health,
Xoriant,
Rom Technologies, Inc.,
Citadel,
Immusoft,
Forge Arms,
Ao Bioconsulting Llc,
Gilead Sciences.
Exir Bio's categories are Biotechnology Research
Exir Bio's founding year is 2022
